Cain H, Macpherson I R, Beresford M, Pinder S E, Pong J, Dixon J M
Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Clin Oncol (R Coll Radiol). 2017 Oct;29(10):642-652. doi: 10.1016/j.clon.2017.06.003. Epub 2017 Jun 29.
Neoadjuvant treatment offers a number of benefits for patients with early breast cancer, and is an important option for consideration by multidisciplinary teams. Despite literature showing its efficacy, the use of neoadjuvant therapy varies widely. Here we discuss the clinical evidence supporting the use of neoadjuvant therapy in early stage breast cancer, including patient selection, monitoring response, surgery and radiotherapy considerations, with the aim of assisting multidisciplinary teams to determine patient suitability for neoadjuvant treatment.
新辅助治疗为早期乳腺癌患者带来诸多益处，是多学科团队需要重点考虑的重要选择。尽管有文献表明其疗效，但新辅助治疗的使用差异很大。在此，我们讨论支持在早期乳腺癌中使用新辅助治疗的临床证据，包括患者选择、疗效监测、手术及放疗考量，旨在帮助多学科团队确定患者是否适合新辅助治疗。
